VWM
CATX icon

Vermillion Wealth Management’s Perspective Therapeutics CATX Stock Holding History

Vermillion Wealth Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$662 Hold
194
– – ﹤0.01% 1487
2026
Q1 		$809 Hold
194
– – ﹤0.01% 876
2025
Q4 		$534 Hold
194
– – ﹤0.01% 572
2025
Q3 		$665 Hold
194
– – ﹤0.01% 1464
2025
Q2 		$667 Hold
194
– – ﹤0.01% 493
2025
Q1 		$413 Hold
194
– – ﹤0.01% 1261
2024
Q4 		$619 Buy
+194
New +$1.58K ﹤0.01% 496

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Vermillion Wealth Management's CATX Position: Q2 2026 in Review

Vermillion Wealth Management held its Perspective Therapeutics (CATX) position steady in Q2 2026 at 194 shares worth $662. The position accounts for ﹤0.01% of the portfolio, ranked #1487.

Vermillion Wealth Management first reported a position in CATX in Q4 2024 and has held it in 7 quarters since. The position peaked at $809 in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Vermillion Wealth Management held 194 shares of Perspective Therapeutics worth $662 as of Q2 2026.
  • Vermillion Wealth Management left its Perspective Therapeutics share count unchanged in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of Vermillion Wealth Management's portfolio in Q2 2026, its #1487 holding.
  • Vermillion Wealth Management first reported a position in Perspective Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Vermillion Wealth Management's Perspective Therapeutics position peaked at $809 in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.